Trefoil Therapeutics has raised $28 million in Series A financing, which will be used to support its phase 2a proof-of-concept study in corneal endothelial dystrophy, the company announced in a press release.
Trefoil Therapeutics has raised $28 million in Series A financing, which will be used to support its phase 2a proof-of-concept study in corneal endothelial dystrophy, the company announced in a press release.